Brief: Argenx Announces European Commission Approval Of Vyvgart Subcutaneous Injection
20/06/2025 18:01
June 20 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES EUROPEAN COMMISSION APPROVAL OF VYVGART SUBCUTANEOUS INJECTION FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY EC APPROVES VYVGART SC FOR CIDP IN EUROPE FIRST NOVEL MECHANISM OF ACTION FOR CIDP IN 30 YEARS EC APPROVES VYVGART 1000MG SC INJECTION FOR CIDP EC APPROVAL APPLIES TO EU, ICELAND, LIECHTENSTEIN, NORWAY Source text: nGNXbB5bzc Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))